| Literature DB >> 29258604 |
Michelle D Robinson1,2,3,4, Ina Mishra1,5, Sneha Deodhar1, Vipulkumar Patel1,5, Katrina V Gordon1, Raul Vintimilla6, Kim Brown6, Leigh Johnson6, Sid O'Bryant6, David P Cistola7,8,9,10,11.
Abstract
BACKGROUND: Metabolic syndrome (MetS) is a highly prevalent condition that identifies individuals at risk for type 2 diabetes mellitus and atherosclerotic cardiovascular disease. Prevention of these diseases relies on early detection and intervention in order to preserve pancreatic β-cells and arterial wall integrity. Yet, the clinical criteria for MetS are insensitive to the early-stage insulin resistance, inflammation, cholesterol and clotting factor abnormalities that characterize the progression toward type 2 diabetes and atherosclerosis. Here we report the discovery and initial characterization of an atypical new biomarker that detects these early conditions with just one measurement.Entities:
Keywords: Atherosclerosis, cardiovascular disease; Inflammation, dyslipidemia, magnetic resonance relaxometry; Insulin resistance; Metabolic syndrome; T2, transverse relaxation time, type 2 diabetes mellitus
Mesh:
Substances:
Year: 2017 PMID: 29258604 PMCID: PMC5738216 DOI: 10.1186/s12967-017-1359-5
Source DB: PubMed Journal: J Transl Med ISSN: 1479-5876 Impact factor: 5.531
Bivariate Huber correlation coefficients for water T2
| Biomarkera,b,c | n | Plasma water T2 | n | Serum water T2 |
|---|---|---|---|---|
| Insulin and glucose markers | ||||
| McAuley Indexd | 70 | + 0.64**** | 69 | + 0.70**** |
| Insulin C-peptide | 70 | − 0.65**** | 69 | − 0.45**** |
| HOMA-IRd (insulin c-peptide) | 70 | − 0.64**** | 69 | − 0.46**** |
| Insulin | 70 | − 0.57**** | 69 | − 0.60**** |
| HOMA-IRd (insulin) | 70 | − 0.56**** | 69 | − 0.58**** |
| QUICKId | 70 | + 0.60**** | 69 | + 0.57**** |
| FIRId | 70 | − 0.58**** | 69 | − 0.59**** |
| Glucose/insulin ratiod | 70 | + 0.55**** | 69 | +0.58**** |
| Glucose | 70 | − 0.28* | 69 | − 0.28* |
| HbA1c | 69 | − 0.54**** | 69 | − 0.43*** |
| Proinsulin | 42 | − 0.53*** | 43 | − 0.60*** |
| Protein, viscosity and liver function markers | ||||
| Total protein, serum | 69 | − 0.56**** | 68 | − 0.79**** |
| Serum globulins | 69 | − 0.53**** | 68 | − 0.65**** |
| Serum viscosity | 65 | − 0.30* | 67 | − 0.45*** |
| Total protein, plasma | 41 | − 0.55*** | 42 | − 0.72**** |
| Plasma globulins | 41 | − 0.66**** | 42 | − 0.69**** |
| Plasma viscosity | 51 | − 0.47*** | 52 | − 0.56**** |
| Alanine aminotransferase (ALT) | 52 | − 0.37** | 50 | − 0.35** |
| Lipid and lipoprotein markers | ||||
| Apolipoprotein B (apoB) | 70 | − 0.55**** | 69 | − 0.52**** |
| Non-high-density lipoprotein cholesterol | 70 | − 0.52**** | 69 | − 0.52**** |
| Low-density lipoprotein cholesterol (LDL-C) | 70 | − 0.50**** | 69 | − 0.53**** |
| LDL/HDL ratio | 70 | − 0.54**** | 69 | − 0.58**** |
| Total cholesterol | 70 | − 0.50**** | 69 | − 0.51**** |
| LDL particle number (LDL-P) | 70 | − 0.52**** | 68 | − 0.54**** |
| Triglycerides (TG) | 70 | − 0.54**** | 69 | − 0.54**** |
| TG/HDL ratio | 70 | − 0.46**** | 69 | − 0.49**** |
| Phospholipids | 65 | − 0.44*** | 66 | − 0.41** |
| Very low-density lipoprotein-chol. (VLDL-C) | 63 | − 0.44*** | 62 | − 0.49**** |
| Intermediate-density lipoprotein-chol. (IDL-C) | 63 | − 0.39** | 62 | − 0.50**** |
| Remnant-cholesterol (Rem-C)e | 63 | − 0.44*** | 62 | − 0.53**** |
| Apo B/Apo A–I ratio | 63 | − 0.53**** | 62 | − 0.56**** |
| Inflammation and blood cell markers | ||||
| White blood cell count (WBC) | 69 | − 0.58**** | 68 | − 0.47**** |
| Neutrophil count | 69 | − 0.41*** | 68 | − 0.37** |
| Lymphocyte count | 69 | − 0.40*** | 68 | − 0.36** |
| C-reactive protein (CRP) | 69 | − 0.51**** | 68 | − 0.31** |
| Serum % globulins | 69 | − 0.46**** | 68 | − 0.50**** |
| Plasma % globulins | 41 | − 0.56*** | 42 | − 0.45** |
| Fibrinogen | 43 | − 0.65**** | 44 | − 0.40** |
| Complement C3c | 40 | − 0.52*** | 41 | − 0.44** |
| Complement C4c | 40 | − 0.59**** | 41 | − 0.43** |
| Electrolyte markers | ||||
| Lactate | 41 | − 0.53*** | 42 | − 0.49*** |
| Anion Gap, uncorrected | 69 | − 0.55**** | 68 | − 0.43*** |
| Anion Gap, corrected for [albumin] | 68 | − 0.44*** | 67 | − 0.39*** |
| Cl− + CO2 (HCO3 −) | 69 | + 0.36** | 68 | + 0.30* |
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001
aAll blood samples were collected in the early morning following a 12-h overnight fast
bThis table includes only those biomarkers that were unambiguously correlated with both plasma and serum water T2. Results for markers that correlated with plasma or serum water T2, but not both, are discussed in the text and provided in Additional file 1: Tables S1 and S2. Ambiguous correlations are discussed in “Methods” section
cMany of the variables were natural-log transformed in order to meet the normality condition, an assumption inherent to the Pearson correlation. The correlation coefficients reported here and in Additional file 1: Tables S1 and S2 are for the ln-transformed variables, except the McAuley Index and QUICKI, as these indices are inherently ln-transformed. Other variables that were normally distributed and analyzed without ln transformation were plasma and serum T2, total serum and plasma protein, serum and plasma globulins and % globulins, serum and plasma viscosity, HbA1c, LDL-C, LDL-P, total C, apolipoprotein B, lymphocyte and platelet counts, lactate, and complement C3c
dAs defined elsewhere: McAuley Index [26], HOMA-IR [66, 67], FIRI [68], QUICKI [69], and G/I ratio [70]
eRemnant cholesterol is defined as intermediate-density lipoprotein (IDL) plus VLDL3, as determined using the vertical autoprofile method [71]
Mean plasma water T2 values for conditions and measures associated with early metabolic syndrome
| Conditions and measuresa | Cutoff value | Mean plasma T2 (ms) ± S.E. | |||
|---|---|---|---|---|---|
| No | Yes | Δb | Odds ratiob | ||
| Hyperinsulinemia (H) | Any of 3 below | 796.1 ± 7.9 | 728.7 ± 8.4 | 67.4**** | 9.5 (2.9–32.5)**** |
| High fasting insulinc | ≥ 10.0 μIU/mL | 786.6 ± 7.4 | 721.7 ± 10.2 | 65.0**** | |
| High insulin C-peptidec | ≥ 2.3 mg/mL | 780.7 ± 8.0 | 733.1 ± 11.1 | 47.6*** | |
| Low McAuley Indexd | ≤ 6.07 | 778.1 ± 7.2 | 718.1 ± 13.3 | 60.0*** | |
| Dyslipidemia (D) | Any of 3 below | 798.1 ± 8.6 | 734.3 ± 8.1 | 63.8**** | 5.8 (2.3–15.6)**** |
| High non-HDL-Cc | ≥ 149 mg/dL | 782.4 ± 7.9 | 729.8 ± 10.9 | 52.6*** | |
| Small, dense LDL | Pattern B/AB | 778.0 ± 8.1 | 736.4 ± 11.6 | 41.6** | |
| High LDL-Pc | ≥ 1408 nM | 779.1 ± 8.0 | 734.2 ± 11.5 | 44.9** | |
| Inflammation (I)e | Any of 3 below | 808.3 ± 9.4 | 738.4 ± 7.3 | 69.9**** | 10.4 (3.2–35)**** |
| High CRPc | ≥ 2.5 mg/L | 778.4 ± 7.6 | 725.1 ± 12.9 | 53.2*** | |
| High WBC countc | ≥ 6.92 × 103/μL | 780.3 ± 8.3 | 737.3 ± 10.8 | 43.0** | |
| High serum globulinsc | ≥ 2.9 g/dL | 788.5 ± 7.7 | 725.8 ± 9.7 | 62.7**** | |
| Electrolyte abnormal | Any of 3 below | 784.8 ± 10.3 | 747.3 ± 8.8 | 37.5** | 1.6 (1.1–2.3)* |
| Low (Cl− + CO2)f | ≤ 126 meq/L | 776.5 ± 9.0 | 745.6 ± 10.3 | 30.8* | |
| High anion gapc | ≥ 17.8 meq/L | 777.8 ± 7.9 | 731.6 ± 11.6 | 46.2** | |
| High anion gap corr.g | ≥ 17.7 meq/L | 776.8 ± 8.1 | 742.0 ± 11.3 | 34.8* | |
| Metabolic syndrome | Ref. [ | 776.0 ± 7.4 | 721.6 ± 14.1 | 54.5** | 2.7 (1.2–5.9)** |
| H + ≥ 1 other condition | See above | 796.8 ± 7.6 | 725.8 ± 8.3 | 71.1**** | 15 (4–63)**** |
| H + ≥ 2 other conditions | See above | 792.6 ± 6.9 | 716.5 ± 9.0 | 76.1**** | 17 (4–73)**** |
| H + D + I | See above | 786.5 ± 6.5 | 705.0 ± 10.6 | 81.4**** | 24 (5–-124)**** |
* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
aThis analysis included variables collected in both Phase 1 and Phase 2 of this study (n = 72)
bMean difference (Δ) and odds ratio (95% confidence limits) for the mean difference shown one column to the left
cTop tertile of subjects in this study
dObtained using formula in abstract of ref [26], with insulin = 12.2 μIU/mL and triglyceride = 1.5 mM as input
eFor this row, the Welch test was used in place of the t test, as equal variances could not be confirmed
fTotal measured anions, where ~ 95% of total CO2 is HCO3 −; bottom tertile of subjects in this study
gAnion gap corrected for albumin concentration using regression residuals; top tertile of subjects in this study
Characteristics of the study population, n = 72
| Parameter | Mean ± S.D.a | Rangea | Reference valuesb |
|---|---|---|---|
| Age | 39.5 ± 15.3 | 23–80 | n/a |
| Gender | n/a | 34 female, 38 male | n/a |
| Body-mass index (kg/m2) | 26.1 ± 4.9 | 18.2–45.1 | < 25 normal weight, 25–30 overweight, > 30 obese |
| Plasma T2 (ms) | 764.4 ± 58.7 | 631–887 | ≥ 745.0c |
| Serum T2 (ms) | 818.4 ± 56.7 | 692–927 | ≥ 811.8c |
| Glucose (mg/dL) | 90.9 ± 7.7 | 71–115 | < 100 non-diabetic |
| HbA1c (%) | 5.5 ± 0.3 | 4.7–6.2 | < 5.7 (non-diabetic) |
| Insulin C-peptide (ng/mL) | 2.0 ± 0.9 | 0.7–5.1 | 0.8–3.9 (> 2.85, IRd) |
| Insulin (μU/mL | 9.1 ± 6.0 | 2.2–40.1 | 2.0–19.6 (> 12.2, IRd) |
| Total serum protein (g/dL) | 7.1 ± 0.4 | 6.2–8.0 | 6.1–8.1 |
| Serum albumin (g/dL) | 4.5 ± 0.3 | 3.6–5.1 | 3.6–5.1 |
| Serum globulins (g/dL) | 2.7 ± 0.4 | 1.8–3.3 | 1.9–3.7 |
| Triglycerides (mg/dL) | 117.6 ± 60.0 | 42–321 | < 150 |
| Total cholesterol (mg/dL) | 187.0 ± 41.0 | 97–291 | < 200 |
| HDL-C (mg/dL) | 53.3 ± 12.7 | 31–85 | ≥ 40 (male); ≥ 50 (female) |
| LDL-C (mg/dL) | 111.1 ± 34.7 | 42–191 | < 130 |
| WBC count (×103/μL) | 6.5 ± 1.6 | 3.9–11.2 | 3.8–10.8 |
| Neutrophil count (×103/μL) | 3.6 ± 1.2 | 1.8–7.3 | 1.5–7.8 |
|
| 2.3 ± 2.3 | 0.1–9.6 | < 3.0 (low-to-average CV risk) |
| Sodium (mmol/L) | 139.0 ± 2.7 | 131–146 | 135–146 |
| Potassium (mmol/L) | 4.2 ± 0.3 | 3.5–4.8 | 3.5–5.3 |
| Total CO2, serum (mmol/L) | 24.0 ± 2.3 | 16–29 | 19–30 |
aAll blood samples were collected in the early morning after a 12-h overnight fast
bReference values from Quest Diagnostics and Atherotech, except where noted
cCutoff for normoglycemic population established in this study
dInsulin cutoff from McAuley et al. [26]; insulin C-peptide cutoff established by linear regression with inulin
Biomarkers measured in this study; TD-NMR markers: plasma water T2, serum water T2
| Category | Correlation with plasma water T2a | No correlation with plasma water T2a |
|---|---|---|
| Insulin resistance, diabetes and anthropometric markers | Fasting insulin, insulin C-peptide, proinsulin, HbA1c, glucose, HOMA-IR, QUICKI, FIRI, G/I ratio, McAuley Index | Body-mass index, waist circumference, age, resting heart rate |
| Protein, viscosity liver function and amino acid markers | Total serum and plasma protein, serum and plasma globulins, % globulins, viscosity, ALT, GGT, Ser, Asn, Gln, Thr, Tyr | Serum and plasma albumin, IgG, IgM, IgA, AST, homocysteine, and 30 other amino acid and amino acid metabolites |
| Lipid and lipoprotein markers | Total cholesterol, non-HDL-C, LDL-C, LDL-P, VLDL-C, IDL-C, remnant-C, apoB, phospholipids, TG, TG/HDL ratio | Lp(a), HDL-C, HDL2, HDL3, apoAI, apoE, omega-3 index, DHA, AA, EPA, LpPLA2, serum turbidity (O.D.550 nm), free fatty acids |
| Inflammation, acute phase proteins, blood cell and oxidative stress markers | hs-CRP, WBC, neutrophils, lymphocytes, platelets, RDW, MCH, sedimentation rate, fibrinogen, complement C3c, C4c, plasminogen activator inhibitor-1 (PAI-1), α1-acid glycoprotein, interleukin-6 | RBC, HCT, Hb, MCHC, MCV, mean PLT volume, HNE, ORAC total antioxidant capacity, monocytes, eosinophils, basophils, haptoglobin, fibronectin, transferrin, ceruloplasmin, total iron, TIBC, % iron sat., ferritin, sICAM1, adiponectin, factor VII, uric acid, neutrophil elastase, endotoxin, staph. enterotoxin, α2-macroglobulin, α1-antitrypsin, IL-10, TNFα, IL-1β |
| Electrolyte markers | Lactate, Cl−, Cl− + CO2 (bicarbonate), anion gap, anion gap corrected for albumin | Sodium, potassium, calcium |
| Kidney and thyroid markers | BUN, creatinine, eGFR, thyroid stimulating hormone (TSH), free T4 |
aA correlation is defined as p < 0.05 for all three correlation coefficients: Pearson, Spearman, and Huber M-value. For biomarkers in the middle column, the individual coefficients and statistics are provided in Table 3 and Additional file 1: Table S1. A list of abbreviations is provided below
Fig. 1Scatterplots for the bivariate correlations between plasma water T2 values and 6 diagnostic markers: a natural log of insulin C-peptide; b McAuley Index; c total serum protein; d low-density lipoprotein cholesterol; e triglycerides; f complement C3c. Each filled black circle represents a data point for an individual human subject. The red ellipse represents the Huber bivariate normal density at the 95% confidence level
Fig. 2Receiver operator characteristic (ROC) curves to quantify the ability of different diagnostic tests to detect early insulin resistance (metabolic syndrome), as defined by the McAuley Index. Blue (left curve): plasma water T2; Red (middle curve): hemoglobin A1c; Yellow (right curve): glucose. An ideal ROC curve follows the left and top axes and intersects with the (0,1 coordinate)
Fig. 3The distribution of the 72 subjects in this study with respect to metabolic abnormalities. Thirty-one subjects had no identifiable metabolic abnormalities (“Normal Metabolism”), while 41 had early abnormalities, prediabetes and/or clinically-defined metabolic syndrome (MetS). Twenty-five of the 41 met the ADA criteria for prediabetes, and 10 of those 25 also met the harmonized clinical criteria for MetS [4]. The remaining 16 subjects with “Early Abnormalities” were identified by low water T2 values in the absence of prediabetes. Only three of those 16 met the clinical criteria for MetS. Thus, water T2 uniquely identified 13 individuals with abnormalities consistent with early metabolic syndrome
Fig. 4The percent change in mean plasma protein concentration between the low vs. high water T2 groups, using the ROC-established cutoffs defined in the text. The 16 most abundant proteins in plasma are listed from left to right in order of decreasing concentration, with total protein and total globulin concentrations listed at the far right. Together, these 16 proteins accounted for > 99% of the total plasma protein mass. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
Fig. 5A model for the linkage between genetic and environmental factors, metabolic abnormalities, blood biomarkers, and plasma and serum water T2 values